Theiler's murine encephalomyelitis virus (TMEV) infection of the central nervous system is rapidly cleared in C57BL/6 mice by an anti-viral CD8 T cell response restricted by the MHC class I molecule, H-2D b . While the CD8 T cell response against neurotropic viruses is well characterized, the identity and function of the antigen presenting cell(s) involved in this process is(are) less well defined. To address this gap in knowledge, we developed a novel C57BL/6 H- 
INTRODUCTION
Theiler's murine encephalomyelitis virus (TMEV) is a neurotropic picornavirus which has classically been studied as a murine model of multiple sclerosis [1] . Strains of mice susceptible to Daniel's strain virus, such as SJL mice, experience chronic infection and demyelination of the spinal cord. Meanwhile, resistant mouse strains, including C57BL/6 mice, present with acute encephalitis and seizures before clearing TMEV infection [2] [3] [4] . Resistance to TMEV has been linked to the H-2D MHC class I molecules, with various alleles providing different levels of protection [5] [6] [7] . One such MHC class I allele, H-2D b , is expressed in C57BL/6 mice and is capable of presenting the immunodominant viral peptide, VP2 [121] [122] [123] [124] [125] [126] [127] [128] [129] [130] , an essential nine amino acid section of the VP2 capsid protein, against which a particularly robust CD8 T cell response is generated [8] [9] [10] [11] [12] . This epitope, and the cytotoxic T lymphocyte (CTL) response raised against it, are responsible for the clearance of the Daniel's strain of TMEV. The involvement of a singular MHC allele in generating productive T cell responses against TMEV makes this virus an ideal model pathogen for interrogating CD8 T cell priming in the brain [13] . While the dynamics and consequences of the CD8 T cell response in this model infection of the central nervous system (CNS) have been well characterized, the identity of the antigen-presenting cell(s) (APCs) responsible for the initial priming of this response remains undefined.
While the infiltration of antigen-specific CD8 T cells into the brain parenchyma in the context of CNS infection, such as West Nile Virus, is well accepted, the specific antigenpresenting cell type(s) required to prime antiviral CD8 T cells has not been fully defined [14] [15] [16] .
Classically, immune responses against peripheral pathogens are primed by dendritic cells (DCs) [17] . However, this cellular population is largely, but not entirely, absent from the brain parenchyma in the steady state [18] [19] [20] [21] [22] [23] [24] . There is evidence that the minimal population of CNS resident DCs can be further augmented by additional DCs migrating into the brain during periods of inflammation [25, 26] . In contrast, macrophages (MΦs) in the perivascular spaces and microglia in the parenchyma are, at least numerically, the predominant APCs within the CNS. Microglia are best understood in regards to their homeostatic role in the brain as a resident phagocyte. Additionally, they have been shown to have some activity as APCs and to upregulate MHC class I and costimulatory molecules during periods of inflammation [27, 28] .
MΦs are also capable of presenting antigen to T cells in vivo, and the observation of myelinfilled MΦs at the site of multiple sclerosis lesions has raised interest in these APCS as having potential involvement in the priming of autoimmune CD8 T cells [29] [30] [31] [32] . Clarifying the roles these three APCs play, either singularly or in concert, in orchestrating CD8 T cell responses against antigens within the CNS would shed light on APC dynamics in this immune-specialized organ.
We sought to address the gap in knowledge regarding the capacity for DCs and MΦs to prime CD8 T cell responses against viral pathogens in the CNS using a novel transgenic mouse model generated by our research team. We introduced a floxed H- Further, this study is the first to describe a delayed CD8 T cell priming event mediated through APCs in the absence of DC MHC class I. This previously uncharacterized modality of T cell priming might be crucial for long term immunity against brain pathogens and warrants further investigation.
RESULTS

Development of C57BL/6 H-2D b LoxP Mice
Class I conditional knockout mice were developed through construction of an H-2D b transgene, in which the transmembrane (TM) domain is flanked by LoxP sites. This transgene was introduced into C57BL/6 mice deficient in H-2D b and H-2K b , leaving the floxed D b as the only MHC class I molecule expressed by nucleated cells (Fig 1A) [33]. Crossing this transgenic mouse line with mice expressing Cre-recombinase under the CD11c, LysM, or CMV promoter, also on total MHC class I knockout backgrounds, allowed for CD11c+ cell specific, LysM+ cell specific, or ubiquitous ablation of MHC-I expression, respectively ( Fig 1B, Fig 1C, Fig 1D) .
Resultant mice will be referred to as CD11c D b conditional knockout (cKO), LysM D b cKO, CMV D b cKO, or Cre-littermates depending on whether the F1 generation pups inherited the crerecombinase gene from their parent. Both LysM and CD11c driven cre-recombinase models have been well characterized by other groups [34] . Although they have some off-target specificities, they have been found to primarily target MΦ and cDCs, respectively [34] . One potential concern in any MHC class I-deficient model is that natural killer cell mediated cytotoxicity through missing-self recognition might lead to a depletion of that cell population.
However, we did not detect a change in the percentage of CD11c+ cells within the spleens of unchallenged CD11c D b cKO mice, nor of F4/80+ cells within LysM D b cKO mice, relative to
Cre-littermates ( Fig 1E) .
Conditional deletion of H-2D b in CD11c+ cells results in no steady state immune abnormality
Before investigating the immunologic role of H-2D b on APC subsets during intracranial picornavirus infection, we evaluated the potential of our cre-recombinase system to have overt off-target effects on immune system development. Since DCs of both cDC1 and cDC2 lineages have been reported to contribute to thymic selection and the shaping of peripheral T cell repertoires, we sought to ensure that our DC-specific H-2D b depletion strategy did not disrupt thymocyte development. CD11c D b cKO and Cre-littermates presented equivalent levels of H-2D b on total thymic cells [35] . The only discernible difference in the levels of thymocytes across any developmental stage was that observed in the negative control MHC class I total KO animals, whose lack of CD8 T cells is an expected effect of ubiquitous MHC-I deficiency (Fig   2A, Fig 2B, Fig 2C) . Both MΦs and DCs are prevalent in secondary lymphoid organs, so we assessed the TCR Vβ repertoire expressed by the mature splenic T cell pool of naïve animals.
As shown in Figure 3 , we found no difference in the frequency of the Vβ genes employed by CD8 T cells of either LysM D b cKO or CD11c D b cKO animals relative to Cre-littermates, demonstrating that there were no detectable differences in the TCR repertoire of these transgenic animals ( Fig 3A, Fig 3B) . These data demonstrate that the novel H-2D b cKO animals have normal T cell development.
We then assessed H-2D b expression during viral infection, since microglia are known to upregulate CD11c when activated --an event which would occur during acute TMEV infection. Fig 4A, Fig 4B) . These findings together establish a robust model for the cell specific deletion of MHC class I on CD11c+ and LysM+ APCs in the periphery with no gross systemic consequences in the steady state.
CD11c+ cells are critical for rapid priming of CNS infiltrating antiviral CD8 T cells
We next evaluated the consequence of selective ablation of MHC-I restricted antigen presentation ability in the context of T cell priming against viral infections of the CNS. The novel H-2D b cKO transgenic mouse system has laid the groundwork to study the crucial role for DCs and other APC subsets in CD8 T cell priming against CNS pathogens without disrupting other functions of these cell types, such as CD4 T cell priming or cytokine secretion. In summary, adaptive immune responses, and particularly those of CTLs, are pivotal to host defense against viruses. In addition, these lymphocytes, themselves, can be drivers of neuropathology. Therefore a more robust understanding of how APCS drive this form of immunity could have profound impact on the development of effective therapies as well as limiting toxicities that arise from mobilizing activated effector CD8 T cells into the brain [62, 63] .
In furtherance of these goals, we have described herein a cre-recombinase system for the cellspecific deletion of H-2D b on CD11c+ cell populations in C57BL/6 mice. In the process, we have shown these APCs to be the significant driver of the acute CD8 T cell responses against TMEV infection. This work also provokes new questions about additional APC(s) responsible for CTL priming at later time points. Importantly, we introduce a novel transgenic mouse model that can serve as a critical reagent for more detailed investigations of CTL priming both within and outside the CNS moving forward.
METHODS
Generation and crossing of transgenic mice
Animal experiments were conducted in the manner approved by the Mayo Clinic 
TMEV infection and induction of BBB disruption
Infection and BBB disruption were conducted as previously reported [58] . Briefly, animals between 6 and 14 weeks old, were infected intracranially with 2x10 4 PFU of Daniel's Strain TMEV in the right hemisphere of the brain in a total volume of 10μL following anesthetization with 2% isoflurane. Mice were euthanized for flow cytometric analysis, or induced to undergo PIFS, at 7, 14, or 28 dpi. The PIFS model employed by our group involves the tail vein injection of 100μL of a 1mg/mL solution of VP2 121-130 peptide (FHAGSLLVFM) in PBS at either 7 or 14 days after the original TMEV infection (GenScript, Nanjing) [38] [39] [40] [41] [42] [43] .
Animals were observed until they became visibly distressed (hunched and unresponsive), and then were injected via tail vein with 100μL of a 100mg/mL FITC-albumin solution in PBS (Sigma-Aldrich, St. Louis, MO). PIFS induced mice were euthanized 1hr after FITC-albumin injection for analysis.
MRI Analysis
MRI capture and analysis was conducted as previously reported [38] . Briefly, a random subset of animals from each genotype within PIFS experiment cohorts were subjected to T1-weighted gadolinium-enhanced MRI imaging with a Bruker Avance II 7 Tesla vertical bore small animal MRI system (Bruker Biospin, Billerica) roughly 5hr before PIFS endpoint associated behaviors emerged. Mice were injected intraperitoneally with a 100mg/kg dose of gadolinium, anesthetized with 3% isoflurane and, following a 15 minute wait for gadolinium circulation, subjected to a T1-weighted spin echo sequence under maintenance dosing of 1.5% isoflurane.
Their respiratory rate was monitored throughout with an MRI compatible vitals monitoring system (Model 1030, SA Instruments, Inc., Stony Brook, NY). Resultant images were processed with the Analyze12.0 software to generate object maps of regions of gadolinium enhancement.
3D models were generated by overlaying these object maps onto 20% opaque object maps of the entire brain (Biomedical Imaging Resource, Mayo Clinic, Rochester, MN).
FITC-albumin Permeability Assay
A FITC-albumin based permeability assay was conducted as previously reported by our group [39] . In short, the left brain hemisphere taken from FITC-albumin injected animals was homogenized in RIPA buffer (50mM Tris-HCl, 150mM NaCl, 1% NP-40, 0.5% Sodium deoxycholate, 0.1% SDS, and 5mM EDTA) (Boston BioProducts, Ashalnd, MA) along with a protease inhibitor cocktail using a PowerGen 125 homogenizer (Fisher Scientific, Hampton, NH). Samples were subsequently centrifuged for 10min at 4C at 10,000rpm. The supernatant was subjected to a BCA protein assay (Pierce Biotechnology, Waltham, MA) and measured on a Synergy H1 Hybrid Multi-Mode Reader (BioTek, Winooski, VT). After normalizing the samples to the lowest sample concentration through the addition of PBS, the brain homogenates were measured on a fluorescent plate reader at 488nm excitation and 525nm emission.
Confocal Microscopy
Confocal analyses were conducted as previously reported [49] . The right brain hemispheres taken from FITC-albumin injected animals were fresh frozen at -80˚C. For analysis, they were embedded in Tissue-Tek OCT (Sakura Finetek, Torrance, CA) and were sectioned with a cryostat. 10μm coronal sections cut from near the hippocampal formation as previously described were placed on positively charged slides which were washed with PBS before fixation in 4% paraformaldehyde for 15min at room temperature. All slides were washed thrice with 100μL PBS and then incubated for an additional 1hr in 100μL of a 5% normal goat serum and 0.5% Igepal CA-630 solution (Sigma-Aldrich, St. Louis, MO). Samples were subjected to a primary stain with 100μl of a 1:200 dilution rabbit anti-mouse Occludin (clone OC-3F10, Invitrogen, Carlsbad, CA) overnight at 4C. After three washes with PBS, the Alexa Fluor 647 Goat anti-rabbit IgG secondary was applied at a 1:500 dilution in a total volume of 100μl for 1hr (Invitrogen, Carlsbad, CA). After five final washes with PBS, slides were dried and covered with Vectashield medium + DAPI (Vector lab, Burlingame, CA). Images were taken at room temperature using a Leica DM2500 with a 63x oil immersion objective, and were subsequently analyzed with Leica Acquisition Suite software (Wetzlar, Germany).
Flow Cytometry
Flow cytometric measurements were conducted as previously published [49, 64] .
Spleens and thymi harvested from euthanized animals were crushed through a 70um filter into 10mL RPMI to create a single cell suspension. Brains were harvested directly into 5mL RPMI before application of a dounce homogenizer. This brain homogenate was passed through a 70μm filter into a Percoll solution (9mL Percoll, 1mL 10x PBS, and 10mL RPMI) and subsequently centrifuged at 7840xg. After the myelin layer was removed, the remaining 10mL of brain single cell suspension was spun at 400xg for 10min along with the single cell suspensions EtOH), and plaques were counted by hand.
Plaque Assay
Statistical Analysis
All data presented as mean ± standard error of the mean (SEM), and all analyses were conducted with GraphPad Prism 7.0 (La Jolla, CA). Tests used include a two-sided Student's t test, a one-way ANOVA with Holm-Sidak correction for multiple comparisons, and a MannWhitney Rank Sum Test if the data did not follow a normal distribution. 
